Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q2- Text added to 2021 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
New words:
AEs, anemia, arm, Bruton, BTK, CA, cessation, comfort, compelling, competitor, difficult, doublet, employ, employment, failure, FOLFIRINOX, fourth, free, gemcitabine, harboring, heavily, inconvenience, infusion, line, mantle, mechanistic, moiety, moving, mutational, Nasdaq, optimized, orphan, outpatient, plausible, prevent, prolonged, question, rationale, reversible, Rule, schedule, SD, serial, Similarly, superior, superiority, thirteen, thrombocytopenia, tyrosine
Removed:
accumulation, Actinium, Aprea, argenx, Arog, biological, choose, compatible, Daiichi, ENA, escalation, fulvestrant, Geron, gilteritinib, goal, hypomethylating, mechanism, minimal, Molecular, Otsuka, platelet, prioritize, progressive, proof, Rafael, recent, repeat, Sankyo, SE, showed, Squibb, Symposium, vomiting, week
Valuein 2021 Q2 filing- Value in 2021 Q3 filing
Original filings
Filing view